Oncology

Defying cancer

Our defiant goal is to reverse the cancer mortality trend. We’re doing this through a comprehensive pipeline that addresses the hallmarks of cancer. With an emphasis on immuno-oncology and antibody drug conjugates (ADCs), we are unleashing the power of our own immune systems and targeting tumors with lethal drugs.




Our Pipeline

Oncology

Phase 1

Phase 1

  • AZD1775 + durvalumab solid tumours
  • MEDI-565 solid tumours
  • MEDI0562 solid tumours
  • MEDI0562 + durvalumab solid tumours
  • MEDI0562 + tremelimumab solid tumours
  • MEDI0680 solid tumours
  • MEDI1873 solid tumours
  • MEDI4276 solid tumours
  • MEDI9197 solid tumours
  • MEDI9447 solid tumours
  • durvalumab solid tumours
  • durvalumab + Iressa NSCLC
  • durvalumab + MEDI9447 solid tumours
  • durvalumab + dabrafenib + trametinib melanoma
  • durvalumab + monalizumab solid tumours
  • durvalumab + tremelimumab solid tumours
  • selumetinib + durvalumab solid tumours

Phase 2

Phase 2

  • MEDI-573 metastatic breast cancer
  • Tagrisso (AZD9291) + (durvalumab or selumetinib or savolitinib) TATTON advanced EGFRm NSCLC
  • durvalumab bladder cancer
  • durvalumab solid tumours
  • durvalumab + MEDI0680 solid tumours
  • durvalumab + tremelimumab gastric cancer
  • durvalumab +AZD5069 durvalumab +AZD9150 SCCHN

Phase 3

Phase 3

  • durvalumab solid tumours
  • durvalumab PACIFIC stage III NSCLC
  • durvalumab + tremelimumab ALPS metastatic pancreatic ductal carcinoma
  • durvalumab + tremelimumab ARCTIC 3rd-line NSCLC
  • durvalumab + tremelimumab CONDOR 2nd-line SCCHN (PD-L1 negative)
  • durvalumab + tremelimumab DANUBE 1st-line bladder
  • durvalumab + tremelimumab EAGLE 2nd-line SCCHN
  • durvalumab + tremelimumab KESTREL 1st-line SCCHN
  • durvalumab + tremelimumab MYSTIC 1st-line NSCLC
  • durvalumab + tremelimumab NEPTUNE 1st-line NSCLC
  • moxetumomab pasudotox PLAIT hairy cell leukaemia

Oncology News

Join us at MedImmune

Our Great Place to Work strategic initiative offers a dynamic environment that fosters collaboration and innovation. We attract top minds, and we do what it takes to nurture and build talent.